Tesamorelin
Tesamorelin is a stabilized analog of GHRH studied in lipid-distribution and growth-hormone-axis research.
We have not published an audit on Tesamorelin. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
GHRH receptor agonist; GH axis modulation.
Tesamorelin tells your pituitary gland to release more of your own growth hormone in its natural pulsing rhythm, which then drives the body to break down deep belly fat and liver fat more than other fat stores.
Reported side effects
The most common side effects are injection-site reactions like redness, itching, and swelling, along with possible fluid retention, joint pain, muscle aches, elevated blood sugar, and antibody development in about half of long-term users.
Who should avoid it
People with active cancer, pregnancy, a known allergy to tesamorelin or mannitol, or major hypothalamus or pituitary problems should not use tesamorelin, and those with diabetes, a cancer history, or diabetic eye disease should use it only with careful clinician oversight.
What gets monitored
Check blood sugar before starting and at intervals during use. [Source: Peptide Dosing Protocols]
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for Tesamorelin or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| 1-2 mg SC daily at bedtime | once daily at bedtime12+ weeks · Continuous per provider direction | subcutaneous | Commonly published practitioner dosing range - provider confirmation required. |
| 2 mg | Once daily | subcutaneous | Peptide Protocol WikiWhat it saysHide(secondary reference; provider confirmation required). |
| Standard: 2 mg once a day | Once daily26 weeks · Cycle length Planning note 4 weeks 6 vials (10 mg) 28 daily doses needed. | Subcutaneous injection in the abdomen only | Peptide Dosing ProtocolsWhat it saysHide(secondary reference; provider confirmation required). Half-life: Half-Life Tesamorelin 26-38 minutes Sermorelin 11-12 minutes CJC-1295(DAC) ~6-8 days Fe. The standard dosing for Tesamorelin is 2 mg administered once daily. |
| Fat loss stacking reference: 200 mcg (0.2 mg) fasted morning paired with AOD-9604 300 mcg. Cited for visceral fat targeting with Mod GRF 1-29 as a pulse-enhancing partner. | Daily in stack contexts · Morning, fasted | subcutaneous | Peptide Therapy Reference Text, internal KB v4What it saysHide(Aug 2026), secondary reference; provider confirmation required. |
- once daily at bedtime12+ weeks · Continuous per provider direction
- subcutaneous
- Commonly published practitioner dosing range - provider confirmation required.
- Once daily
- subcutaneous
- Peptide Protocol Wiki
What it saysHide
(secondary reference; provider confirmation required).
- Once daily26 weeks · Cycle length Planning note 4 weeks 6 vials (10 mg) 28 daily doses needed.
- Subcutaneous injection in the abdomen only
- Peptide Dosing Protocols
What it saysHide
(secondary reference; provider confirmation required). Half-life: Half-Life Tesamorelin 26-38 minutes Sermorelin 11-12 minutes CJC-1295(DAC) ~6-8 days Fe. The standard dosing for Tesamorelin is 2 mg administered once daily.
- Daily in stack contexts · Morning, fasted
- subcutaneous
- Peptide Therapy Reference Text, internal KB v4
What it saysHide
(Aug 2026), secondary reference; provider confirmation required.
- Commonly 2 mg vials · Reconstitute with sterile/bacteriostatic water
- Reconstitute with bacteriostatic water
Common questions
What is the starting dose of tesamorelin?
Tesamorelin starts at full dose from day one — no ramp-up.
What is tesamorelin's half-life?
Tesamorelin's half-life is about 26 to 38 minutes.
Is tesamorelin FDA-approved?
Yes, tesamorelin was FDA-approved in November 2010 for reduction of excess abdominal fat in HIV-infected adults.
What are the most common side effects of tesamorelin?
The most common side effects are injection-site reactions, fluid retention, joint pain, and muscle aches.
How do you reconstitute tesamorelin?
Add bacteriostatic water slowly down the inside wall of the vial.
Open the reconstitution calculator →How much bacteriostatic water should be added to tesamorelin?
Common setups are 0.5 to 1.0 mL for a 2 mg vial, 1.0 to 2.5 mL for a 5 mg vial, and 2.0 to 5.0 mL for a 10 mg vial.
What results can be expected from tesamorelin?
Phase III trials showed visceral fat reduction of about 12-20% over 26 weeks.
How does tesamorelin compare to sermorelin and CJC-1295?
Tesamorelin is the only one with current FDA approval and Phase III trial data showing visceral fat reduction.
Sources
- 01Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: pooled analysis of two multicenter Phase 3 trials with safety extension data. Journal of Clinical Endocrinology & Metabolism (2010)
- 02Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV (2019)
- 03Fourman LT, Stanley TL, et al. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight (2020)
- 04Fourman LT, Stanley TL, et al. Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach. Scientific Reports (2021)
- 05Grinspoon S, et al. Effects of a Growth Hormone-Releasing Hormone Analog on Endogenous GH Pulsatility and Insulin Sensitivity in Healthy Men. Journal of Clinical Endocrinology & Metabolism (2011)
- 06Ishida J, et al. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications (2020)
- 07U.S. Food and Drug Administration Egrifta SV (tesamorelin) prescribing information. FDA (2024)
- 08U.S. Food and Drug Administration Egrifta WR (tesamorelin) prescribing information. FDA (2025)
- 09Drugs.com Tesamorelin Monograph for Professionals. Drugs.com (2025)
- 10National Institutes of Health LiverTox: Tesamorelin. NCBI Bookshelf (2023)
- 11ClinicalTrials.gov Tesamorelin Effects on Liver Fat and Histology in HIV (NCT02196831). ClinicalTrials.gov (2024)
- 12Falutz J, McLaughlin T, et al. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS (2024)
The reference sections above are imported from our compound knowledge base, which classes the evidence for Tesamorelin as established. That classification is the knowledge base’s, not ours, our own grade appears only where an audit is linked above. Research use only; nothing here is medical advice or a protocol.
Combination stack studied for body recomposition (fat loss and lean-mass support).
AOD9604 is a modified C-terminal fragment of human growth hormone (residues 176-191), studied in lipid metabolism research models.
Blend of cagrilintide (amylin analog) and retatrutide (triple GLP-1/GIP/glucagon agonist), studied for weight management.
Blend of cagrilintide (amylin analog) and tirzepatide (GIP/GLP-1 dual agonist), studied for weight management.
Investigational fixed-dose combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist), studied once weekly for weight management.
GHRH analog discussed for GH axis support.